Format

Send to

Choose Destination
J Neural Transm (Vienna). 2018 Oct;125(10):1417-1432. doi: 10.1007/s00702-018-1910-4. Epub 2018 Aug 25.

Diagnostic biomarkers for Parkinson's disease at a glance: where are we?

Author information

1
Neurology Unit, L. Sacco University Hospital, Milan, Italy.
2
Department of Health Sciences, "Aldo Ravelli" Research Center for Neurotechnology and Experimental Brain Therapeutics, University of Milan and ASST Santi Paolo e Carlo, Milan, Italy. alberto.priori@unimi.it.

Abstract

Parkinson's disease (PD) is a neurodegenerative disorder whose aetiology remains unclear: degeneration involves several neurotransmission systems, resulting in a heterogeneous disease characterized by motor and non-motor symptoms. PD causes progressive disability that responds only to symptomatic therapies. Future advances include neuroprotective strategies for use in at-risk populations before the clinical onset of disease, hence the continuing need to identify reliable biomarkers that can facilitate the clinical diagnosis of PD. In this evaluative review, we summarize information on potential diagnostic biomarkers for use in the clinical and preclinical stages of PD.

KEYWORDS:

Biomarkers; Diagnosis; Parkinson’s disease

PMID:
30145631
PMCID:
PMC6132920
DOI:
10.1007/s00702-018-1910-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center